A team of Discovery Park scientists researching human neurological and psychiatric health conditions is expanding research opportunities for its Kent-based team in mainland Europe, by opening an additional laboratory in Poland.
The Transpharmation team only announced the move of its headquarters and main laboratory to Discovery Park itself in November 2020, and started working from its laboratories there this month (February 2021).
The additional Poland expansion means newly-recruited scientists, students and research assistants at Discovery Park will be able to forge new relationships with the University of Warmia and Mazury in Poland – maintaining an important research connectivity post-Brexit.
Transpharmation already has other science bases at the Royal Veterinary College (RVC) and The London Bioscience Innovation Centre in London, England, and Trinity College Institute of Neuroscience (TCIN) in Dublin, Ireland.
Transpharmation CEO Dr Mark Duxon said: “With travel restrictions ebbing and flowing as we deal with the effects of Covid, having laboratories within England, mainland Europe and Ireland will give our clients flexible options in the future and allow us to complete experiments; having our other centres means we can still support our client’s pre-clinical testing across the Transpharmation network as local restrictions on movements change.”
Mayer Schreiber, CEO of Discovery Park, said: “We were delighted to welcome Transpharmation here last year, bringing its team of scientists who are now hard at work. The company’s new links with Poland show it leveraging its Discovery Park headquarters to access continental Europe, helping to drive its business forward.”
Transpharmation, which marked its 10th anniversary in 2020, provides research experiments, expertise, and data to show how potential new medicines might interact with the body and possess the ability to treat human diseases. It has more than 100 clients internationally.
